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Abstract
Awareness of the importance of chronic adult hydrocephalus has been raised again with the recent
emergence of epidemiological studies. It is estimated that between 5 and 10% of patients suffering
from dementia might, in fact, have chronic hydrocephalus. Although, surgical diversion of the
cerebrospinal fluid (CSF) represents the only known procedure able to treat the symptoms of this
condition, the selection of surgical patients has always been problematic. In the last 40 years, we
have become wiser in using appropriate diagnostic tests for the selection of these patients;
however, the area of biological markers has so far been overlooked in this condition, in contrast
to that for other neurodegenerative disorders and dementias. Biomarkers are biological substances
that may be used to indicate either the onset or the presence, and the progression of a clinical
condition, being closely linked to its pathophysiology. In such a setting they might assist in the more
appropriate selection of patients for shunt surgery. In this article, we have reviewed research
carried out in the last 25 years regarding the identification of serum and CSF biomarkers for
chronic hydrocephalus, discussed the potential for each one, and finally discussed the limitations
for use, as well as future directions and possibilities in this field. It is concluded that tumour-
necrosis factor, tau protein, lactate, sulfatide and neurofilament triple protein are the most
promising CSF markers for chronic hydrocephalus. At present however, none of these meet the
criteria required to justify a change clinical practice. In the future, collaborative multi-centre
projects will be needed to obtain more substantial data that overcome the problems that arise from
small individual and uncoordinated studies.
Background
Chronic communicating hydrocephalus in adults is now
recognised as one of the causes for reversible dementia,
with an occurrence of 1–10% among patients with a diag-
nosis of dementia [1,2]. Data from Sweden suggest an
incidence of 3.36 surgical operations for chronic hydro-
cephalus per 100,000 inhabitants per year [3,4]. However,
it is thought that normal pressure hydrocephalus is signif-
icantly underestimated because many cases go unreported
and untreated [5]. The term chronic hydrocephalus of
adult-onset (CAH) encompasses a variety of conditions
that include normal pressure hydrocephalus (NPH) of the
idiopathic or secondary variety (depending on whether
there is a known cause such as trauma, subarachnoid
haemorrhage, meningitis, and tumour), communicating
hydrocephalus due to a disturbance of CSF dynamics,
non-tumoural aqueductal stenosis, and compensated
arrested hydrocephalus. We are still in the process of
understanding the pathophysiological mechanisms
underlying hydrocephalus in adults, even though 40 years
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have passed since Hakim and Adams first coined the term
"Normal Pressure Hydrocephalus" [6].
Biological markers have traditionally been used in clinical
practice in order to support a diagnosis, or monitor the
progression of a disease by measuring levels longitudi-
nally. The definition as given by the Biomarkers Defini-
tion Working Group was "A characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes or pharmacological responses to
a therapeutic intervention."[7]. Biomarkers can assist us in
this task as they provide an insight to the changes of the
cerebral milieu associated with the condition. In order for
their use to be established in routine clinical practice, they
should demonstrate high sensitivity and specificity.
Biomarkers have long been used in the neurosciences for
these exact reasons [8-13]. Some well established biomar-
kers in the field of neurodegenerative disorders and
dementias are the neurofilament light chain polypeptide
for multiple sclerosis (MS) [14], and tau protein in Alzhe-
imer's dementia (AD) [15]. Extensive research has already
been carried out to document the hydrocephalus-induced
changes in the composition of cerebrospinal fluid (CSF)
[16].
Serum biomarkers have played an important role in other
neurological conditions, due to the relative accessibility of
samples [17,18]. However, CSF remains the primary fluid
of choice to monitor these changes. The concept of the
"sink action" of the CSF was first introduced by Davson in
1962 to highlight this potential [19]. The aim of this
paper is to review the role that biomarkers play in the
diagnosis and monitoring of the clinical progression of
CAH, and to discuss current research and future perspec-
tives. We have summarised the current literature in Table
1 [see Additional file 1].
Search strategy
A Medline search using Pubmed and EMBASE databases
was carried out for the years 1980–2005, using the key
words biomarkers, biological markers, CSF, serum, communi-
cating hydrocephalus, and normal pressure hydrocephalus. The
search was limited to adults, and to abstracts in the Eng-
lish language. Thirty articles were retrieved and reviewed
(see table 1). Articles from animal studies were reviewed
and used only to support relevant human findings. A
review of citations within the retrieved references was also
carried out for earlier relevant references.
Serum biomarkers
Despite serum being an easily accessible biological fluid,
only four studies on biomarkers in adult hydrocephalus
have been identified, thus demonstrating that there is an
open field for the discovery of serum biomarkers in CAH.
Vasopressin plasma levels were studied in 11 patients and
compared to controls. No significant difference was found
between the two groups [20] and similar results were
found in another study with 18 patients [21].
Glycoprotein D2 serum levels were measured in 13
patients with NPH and there was no difference compared
to control subjects. However, the mean values were signif-
icantly lower when compared to those of patients suffer-
ing from primary degenerative dementia of Alzheimer's
type. Unfortunately, the authors do not comment on the
significance of this finding and neither were the findings
correlated with imaging or with CSF dynamic studies [21].
Preoperative melatonin levels were studied in six patients
with NPH and were found to be lower than controls. Post-
operative values did not differ significantly, but shunting
restored the preoperative deranged diurnal rhythm of
melatonin [22].
Cerebrospinal fluid biomarkers
Biomarkers in the CSF are potentially more useful because
they provide an insight into changes in the brain milieu
associated with the condition, and consequently more
research has been undertaken on the composition of the
CSF. It is assumed that ventricular CSF will reflect the
changes happening in the brain parenchyma, and more
specifically in the periventricular white matter. Ideally,
levels of biomarkers should be measured before and after
surgical diversion of the CSF, in order to obtain clinically
useful indices for the diagnosis and progression of the dis-
ease. Initial attempts took place in the early 80's [23].
There are some reasons why good experimental criteria
have not always been met: 1) universally accepted out-
come scales have not been produced until recently, mak-
ing comparison between different studies and different
groups difficult [24], 2) NPH is a relatively rare disorder
and it is only recently that there is increased awareness
about its importance, 3) CSF is not always available for
repeated sampling, especially in pre-shunt patients with
no accessible route into the ventricles (reservoir). How-
ever, this latter cohort of patients may provide a better
insight into the pathophysiology, because after shunt
insertion the CSF dynamics are altered.
1. Neuropeptides
• Somatostatin
Somatostatin (SOM) in the CSF has been measured by
two groups, in 1991 [25] and in 2001 [26]. In the study by
Wikkelso, CSF SOM levels were significantly lower (p <
0.05) in NPH patients when compared to the control
group and Poca et al also observed the same. They sug-
gested that the decrease could be the result of damage to
the cortical neurons and the nerve terminals of the
hypothalamus that normally have high concentrations of
SOM. The normal concentrations of SOM in these struc-Cerebrospinal Fluid Research 2006, 3:11 http://www.cerebrospinalfluidresearch.com/content/3/1/11
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tures are selectively impaired in experimental hydroceph-
alus [27,28].
Following shunting, SOM concentration significantly
increased compared to preoperative values. The authors
also detected a significant correlation with visual memory
performance (r = 0.57; p = 0.032) and with visuomotor
speed (r = -0.55; p = 0.05), demonstrating that higher con-
centrations of SOM were associated with better visual
memory and increased speed of mental processing, fea-
tures that are known to be deranged in NPH. These asso-
ciations did not persist after surgery. After shunting,
changes in SOM concentrations correlated significantly (r
= 0.66; p = 0.01) with improved daily life activities (meas-
ured with the Rapid Disability Rating Scale-2 (RDRS-2).
In another smaller study, levels of SOM were lower in the
idiopathic NPH (iNPH) group when compared to con-
trols, but were not correlated with either Mini Mental
State Examination (MMSE) scores or the Blessed dementia
scale [29]. The modulatory role of somatostatin in cogni-
tion has already been proposed [30].
• Vasoactive Intestinal Peptide
Wikkelsö in 1985 examined the role of the vasoactive
intestinal peptide (VIP) in the pathogenesis of NPH and
in multi-infarct dementias [31]. The preoperative concen-
tration of VIP in CSF was significantly lower in NPH when
compared to controls, but increased postoperatively. The
rationale behind the study was that VIP is a potent vasodi-
lator and therefore may play a role due to the presence of
chronic ischemia [32]. These results were verified again in
a later study [25] by the same group. Tullberg et al. com-
pared the levels of VIP in 43 patients with NPH and 19
with subcortical arteriosclerotic encephalopathy (SAE)
and found the CSF levels of VIP higher in patients with
SAE than with NPH [33]. They also noticed that the group
of NPH patients suffering from cerebrovascular disease
demonstrated higher VIP concentrations than those with
other aetiologies. They suggest that higher VIP concentra-
tion in patients with SAE could be due to activation of
VIP-ergic neurons to accomplish a compensatory vasodil-
atation. This would not, however, explain why the VIP lev-
els increased following a shunt operation as in the
previous study, since cerebral blood flow has been shown
to be restored postoperatively [34]. Tisell et al compared
the levels of VIP in 18 patients with aqueductal stenosis
and 19 patients with iNPH [35]. The authors correlated
the results with outcomes, concluding that levels of VIP
correlated weakly with postoperative deterioration in
alertness.
• Delta-sleep-inducing peptide
Wikkelsö et al. investigated the role of delta-sleep-induc-
ing peptide (DSIP) in the CSF of ten patients with NPH
and compared the results with that of healthy volunteers
and other dementias [25]. The levels of the peptides were
again decreased in NPH compared to control levels, but
increased significantly in parallel to the clinical improve-
ment following shunting. Since, DSIP is a 9-amino acid
peptide with a role in the normal sleep-wakefulness regu-
lation, the results are not surprising, especially since the
reduction was more pronounced in subjects with worse
psychomotor performance.
• Neuropeptide Y
Reduced levels of neuropeptide Y (NPY) in patients with
NPH has been found in several studies [25,26,36]. Fur-
thermore, it appears that the levels increase following
shunting [26]. Wikkelsö et al. investigated the role of this
neuropeptide in ten patients with NPH compared to lev-
els in other patients with dementia; he also examined and
compared the levels longitudinally three months post
shunting. The percent increase in concentration following
shunting was strongly correlated with percent change in a
functional/activity scale (RDRS-2) [25]. Tisell et al in a
later study, compared the levels in 18 patients with aque-
ductal stenosis and 19 patients with iNPH [35]. The
authors correlated the results with outcomes, concluding
that levels of NPY correlated negatively (r < 0.40) with
postoperative improvement in alertness. However, lower
CSF levels when compared with controls have been found
also in patients with AD [37], therefore reducing the spe-
cificity of this peptide and negating its potential role as a
biomarker.
2. Neurotransmitters
Tullberg et al. extended the range of biomarkers in a later
study by examining the role of 4-gamma aminobutyric
acid (GABA) in addition to the two previously mentioned
biomarkers [33]. Similarly to the previous study, they cor-
related the biomarkers with surgical results. No correla-
tion was found with the results of shunt surgery and the
CSF concentration of GABA. Malm et al. considering that
a similar biochemical disturbance to that of patients with
different forms of dementia, namely disturbance in the
cholinergic, serotonergic and noradrenergic system would
occur in patients with NPH, measured the levels of 3-
methoxy-4-hydroxy-phenylglycol (MHPG), homovanillic
acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA),
acetylcholinesterase (AChE) and butyryl cholinesterase
(BuChE) [38]. They did not observe any significant differ-
ences between patients with NPH, AD, multi-infarct
dementia (MID), and controls regarding the concentra-
tions of HVA, 5-HIAA and MHPG, BuChE. They noticed
reduce AChE activity both in the NPH and AD group
when compared to controls. The levels of these transmit-
ters did not correlate with the degree of ventriculomegaly,
dismissing the possibility of a dilutional effect. They
observed a positive correlation between outflow conduct-
ance in the hydrocephalic group and the concentrationsCerebrospinal Fluid Research 2006, 3:11 http://www.cerebrospinalfluidresearch.com/content/3/1/11
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of HVA, and 5-HIAA. Acetylcholinesterase activity was
positively correlated with MMSE scores. The study high-
lighted the possibility of a common cholinergic distur-
bance in NPH and AD.
Homovanillic acid was further studied by Hildebrand et al
as a reflection of dopamine metabolism, attempting to
correlate the concentration with the clinical triad of gait
disturbance, dementia and urinary incontinence [39]. No
correlation was found in their study and the authors
rejected the potential of HVA as a biomarker for this con-
dition. Similarly, levels of HVA did not differ significantly
between patients with NPH and controls in another study
[33]. Another study did not find any difference in the lev-
els of MHPG, HVA and 5-HIAA between cases of obstruc-
tive hydrocephalus and iNPH [40].
3. Cerebral metabolites
• Lactate
Lactate, an end product of anaerobic glycolysis, possibly
represents the element of chronic ischemia implicated in
the pathophysiology of normal pressure hydrocephalus.
Lactate was studied by Malm et al. in 15 patients with
iNPH and was significantly reduced when compared to
controls (n = 21) [38]. Furthermore, they noticed a posi-
tive correlation between outflow conductance in the
hydrocephalic group and the concentrations of lactic acid.
One would expect the levels of lactate to be increased on
a background of chronic ischemia. Malm explained this
paradox by hypothesizing that a) there is an autoregula-
tory clearance of lactate out of the CSF via a facilitated
transport mechanism in the choroid plexus and the cere-
bral subarachnoid space, b) due to inverse, caudo-rostral,
flow of CSF, there is an accumulation of the metabolite in
the ventricles and consequent transependymal absorption
of lactate, and c) as a result of atherosclerosis and the
pathological changes induced there is an obstacle to tran-
sependymal diffusion of lactate from brain extracellular
fluid to CSF. Nooijen et al. however, reported higher lac-
tate levels in the NPH group when compared to controls,
and significantly higher values when compared with AD
(p = 0.0005, n = 36) and vascular dementia (p <= 0.01, n
= 49) concluding that lactate levels might differentiate
between adult hydrocephalus and patients with Alzhe-
imer's and vascular dementia [41]. Although the latter is a
large cohort observational study with 57 hydrocephalic
patients, the authors did not report correlation with CSF
outflow conductance, ventriculomegaly or with surgical
outcomes.
• Free radicals
Fersten et al. studied the role of free-radical peroxidation
products in the CSF of 24 patients with NPH, and in par-
ticular that of thiobarbituric acid-reactive material
(TBAR), and protein sulfydryl (SH) groups [42]. The
rationale behind the study was that free-radical peroxida-
tion alters the structure of biological membranes and may
therefore be implicated in the pathogenesis of chronic
adult hydrocephalus. The results showed a significant
increase in the levels of TBAR, total and soluble SH
groups, as well as a decrease in the number of protein
thiol groups between the NPH and the control group. The
authors imply that peroxidation, which damages the cyto-
plasmic membranes, might be one of the factors that
affect cognitive functioning.
4. Enzymes
• Neuron Specific Enolase
Nooijen et al. studied the CSF levels of neuron specific
enolase (NSE), a glycolytic enzyme localized in neurons,
in 57 patients with NPH. The levels were lower than both
the control and the Alzheimer's group. However, this dif-
ference was not statistically significant and certainly was
not correlated with surgical outcomes [41]. NSE, was sig-
nificantly higher in the Alzheimer's and vascular dementia
group as compared to the control group, while it did not
differ significantly between the two dementia groups [43].
However, these results were contradicted in another study
[44]. These findings are only suggestive that CSF-NSE has
potential as a non-disease specific marker for the neuronal
degeneration in dementia. NSE as a biomarker in hydro-
cephalus remains even less well established.
• Plasminogen Activator Inhibitor-1
Sutton et al. measured the levels of the plasminogen acti-
vator inhibitor-1 (PAI-1) in the CSF of patients suffering
from various neurological disorders [45]. In the hydro-
cephalic patients the levels were not increased compared
to the levels of control subjects. Interestingly enough, the
levels were increased in the case of Alzheimer's-type
dementia, cerebral infarction and CNS infection. This
finding contradicts results from newborns where high lev-
els have been found in cases of posthaemorrhagic hydro-
cephalus [46,47]. PAI-1 is a 52-kDa glycoprotein, which
under normal conditions is relatively restricted from entry
into the CSF. The study found increased levels particularly
in patients with brain tumours, pointing to possible alter-
ations in the blood-brain barrier. The small number of
patients in the above study, the negative findings, and the
fact that the PAI-1 is found in a variety of neurological dis-
eases excludes the use of this protein as a potential
biomarker for hydrocephalus. However, PAI-1 may play a
role in fibrinolysis occurring after a haemorrhage within
the CNS. In the absence of adequate fibrinolysis, micro
thrombi will obstruct the arachnoid villi and subse-
quently cause fibrosing arachnoiditis affecting the CSF
dynamics.Cerebrospinal Fluid Research 2006, 3:11 http://www.cerebrospinalfluidresearch.com/content/3/1/11
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• Prostaglandin D synthase
Mase et al. measured the levels of prostaglandin D syn-
thase (PGDS) in 14 patients with normal pressure hydro-
cephalus and found them significantly lower when
compared with a control patient and other patients with
dementia patients (Lewy body dementia, vascular demen-
tia, Alzheimer's type) [48]. This enzyme is produced in the
leptomeninges, and the trabecular cells of the arachnoid
membrane and then secreted in the CSF as beta-trace. The
authors conclude that the observed decrease is probably
due to a degenerative change in the arachnoid membrane
and cannot be considered the cause of neurological symp-
toms in the case of NPH. It is unclear whether these
decreased levels were due to decreased CSF production
that reflect arachnoid damage, mere dilution, or to the
disturbance in fluid dynamics.
5. Neural cell-derived proteins
• Myelin Basic Protein
Myelin Basic Protein (MBP) is a known indicator of brain
damage and in particular of demyelination [8,49]. It is
known that in hydrocephalus there is demyelination of
the periventricular white matter and so MBP appears as an
attractive marker to study the degree of this pathological
process. Sutton et al. measured the levels of this protein in
the CSF of hydrocephalic patients with different aetiolo-
gies and proposed that active hydrocephalus produces sig-
nificant periventricular demyelination, probably as the
result of mechanical stretching [34]. Interestingly, the
degree of ventriculomegaly was positively correlated with
the levels of MBP. The findings become more interesting
since we know from the studies of Whitaker et al., that cer-
ebral atrophy is not associated with elevated MBP values
[50]. Later, Longatti et al. in 1993 examined the levels of
MBP pre- and postoperatively. In their study of 17 patients
with hydrocephalus who underwent surgical CSF diver-
sion they observed that the levels of MBP decreased fol-
lowing the shunt operation, suggesting that MBP is an
index of brain damage and its levels could be used as an
indication for shunting [51]. They have not however cor-
related the levels with shunting outcomes. However, high
levels of MBP before shunting may be explained by the
pooling of molecules in stagnant CSF, which then
decrease after flow is restored by shunting. In another
study of 57 patients with NPH, the levels of MBP did not
differ significantly between patients with NPH, vascular
dementia, AD, and controls [41]. However, the levels of
MBP were higher than controls.
Although studies have shown that the MBP levels decrease
in humans postoperatively, different results were
obtained in rats. In order to examine the possibility that
neurons and oligodendrocytes, both of which represent
deteriorating cell populations in hydrocephalus, can be
regenerated by proliferating brain cells, rats with kaolin-
induced experimental hydrocephalus were later injected
with bromodeoxyuridine (BrdU). The BrdU positive cells
for MBP were increased from 17% in the hydrocephalic
group to 33% at an early stage after the shunt procedure,
but were restored to 6% at a later stage after shunting. The
differentiation to mature oligodendrocytes appears to be
inhibited in hydrocephalus even after the shunt procedure
[52]. Del Bigio et al., who measured the degree of myeli-
nation indirectly by measuring the MBP in cerebrum of
rats with experimentally induced hydrocephalus,
observed that with persistent hydrocephalus, the corpus
callosum became thinned, axons were lost, and myelin-
related enzyme activities and proteins were decreased. The
timing of intervention became important as he showed
treatment of hydrocephalus at 1 week largely prevented
the damage while shunting at 4 weeks failed to restore the
injured white matter concluding that hydrocephalus in
the immature rat brain delays myelination, but compen-
satory myelination is possible if treatment is instituted
prior to the development of axonal injury [53]. This find-
ing correlates with our clinical experience on NPH and the
importance of shunting patients as soon as possible in
order to achieve the best clinical outcome.
• S-100b
The presence of this protein in blood points to the func-
tional and/or morphological disruption of the blood-
brain barrier [54]. It is a major protein of the cytosol pre-
dominantly found in glial cells. Increased levels have
already been found in cases of astrogliosis [55] and hydro-
cephalic children [54]. S-100b levels in the CSF, were
studied by Nooijen et al. who showed that S-100b levels
did not differ between patients with NPH (n = 44), and
controls [41], and therefore its role as a marker in chronic
adult hydrocephalus is doubtful.
• Nerve Growth Factor
Nerve Growth Factor (NGF) is known to promote neuro-
nal recovery from injury and age-related atrophy, being
also important in the regeneration in the brain. NGF is
not normally detectable in innervated tissues, but abla-
tion of the innervating neurons leads to the production of
measurable NGF in the target tissues [56]. Increased NGF
mRNA levels have been detected in the medial septal
nucleus, striatum and corpus callosum in experimentally-
induced hydrocephalus in rats [57]. Yang et al. investi-
gated the role of NGF in the pathogenesis of hydrocepha-
lus. They measured the levels of NGF in nine adult
patients with high pressure hydrocephalus (the authors
define high pressure as CSF pressure >10 cm H20) and
seven patients with ex-vacuo hydrocephalus [58]. The lev-
els were significantly higher postoperatively in the second
group, despite the fact that no significant difference
existed perioperatively. The results suggested that the neu-
ronal injury was more severe in the ex-vacuo category,Cerebrospinal Fluid Research 2006, 3:11 http://www.cerebrospinalfluidresearch.com/content/3/1/11
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however one may argue that the last measurement was
made only four days postoperatively. No correlation was
made with surgical results. In a similar study Hochhaus et
al. measured the levels of NGF and neurotrophin-3 (NT-
3) in 42 hydrocephalic children. The levels of both were
again elevated in comparison to controls, however the
results were only correlated with presenting symptoms
and not with outcomes [59]. Increased levels of NGF
when compared to controls have been verified in another
study of 16 children with communicating hydrocephalus
[56]. These findings suggest the possibility that the eleva-
tion of NGF concentration in CSF was caused by increased
generation of glial cells that resulted from brain damage.
• Tau protein
Kudo et al. studied the role of tau protein by measuring
the levels in 20 patients with NPH. Tau concentrations
were elevated compared to those of orthopaedic controls
[60]. The results of his study were not correlated with sur-
gical outcomes. The levels of the protein were positively
correlated, however, with the severity of dementia and
with urinary incontinence but not with gait. Tisell et al
also compared the levels of tau protein in 18 patients with
aqueductal stenosis and 19 patients with iNPH, conclud-
ing that the levels of tau have no correlation with clinical
improvement [35]. Tau protein, a microtubule-associated
protein has been found to be elevated in the CSF of
patients suffering from Alzheimer's disease [15], as well as
in patients with Lewy body dementia, corticobasal degen-
eration [61], and Creutzfeldt-Jakob disease [62] indicat-
ing that it is a marker of neuronal degeneration.
Lins et al. measured the immunoreactivity of amyloid beta
peptide (1–42, Ab42-IR) and tau protein (total tau immu-
noreactivity (TTIR) in 12 patients with NPH, and com-
pared them with the levels of an equal number of patients
suffering from vascular dementia, Alzheimer's disease,
Parkinson's disease without dementia and 24 controls
[63]. TTIR levels in NPH were not significantly changed
when compared with the other causes of dementia and
controls, whereas Ab42-IR was significantly decreased
when compared with Parkinsonian patients and control
subjects. The authors combined the results of both mark-
ers in a single plot as a method to discriminate between
different groups of dementia; all the NPH patients were
within the predicted area. Increased levels of TTIR are
believed to reflect ongoing neuronal and axonal degener-
ation or damage, whereas decreased Ab42 may be the
result of increased recruitment of Ab42 from the CSF and
the brain interstitial fluid to deposits in the form of
plaques or decreased secretion into the CSF [64]. A recent
experimental study in rats with kaolin-induced hydro-
cephalus verified the above results showcasing increased
accumulation of Ab42 in the periventricular area, around
the cortical vessels and the cortical parenchyma; the size
of the deposits correlated well with the duration of the
condition [65].
• Glial Fibrillary Acidic Protein
GFAP is a non specific marker indicating gliosis [66,67].
Tullberg et al. were the first to find a useful biomarker
associated with the progression of NPH. They measured
the CSF levels of GFAP in 65 patients with NPH (21 of
which had iNPH), and correlated them with preoperative
clinical presentation and signs. They observed a two-fold
increase in GFAP levels when compared to controls [68].
Similar results regarding GFAP were verified in an earlier
study by Albrechtsen et al. [69]. GFAP did not seem to cor-
relate with severity of symptoms or presentation and had
no correlation with the outcome of shunt surgery. In par-
ticular, GFAP in CSF suggests an irreversible damage to
astrocytes, since GFAP is not secreted by astrocytes.
• Neurofilament triplet proteins
Neurofilament proteins are Type III intermediate filament
proteins that assemble into neurofilaments, the major
cytoskeletal element in nerve axons and dendrites. They
consist of three distinct polypeptides, the neurofilament
triplet protein (NFL). It has been shown that the metabo-
lism of neurofilaments is disturbed in Alzheimer's disease
[70]. Therefore, NFL may be used as a biochemical marker
of neuronal degeneration and particularly of axonal dam-
age [67]. Tullberg et al. measured the levels of NFL in 65
patients with normal pressure hydrocephalus (21 of the
idiopathic type) and correlated them with preoperative
clinical presentation and signs. They observed a six-fold
increase in NFL levels when compared to controls. NFL as
the authors point out is not specific for NPH and therefore
cannot differentiate between various types of dementia.
This increase in NFL indicates a degeneration of neurons
primarily affecting the axonal region with a loss of inter-
mediate filament protein across deranged cell membranes
into the interstitial fluid. Although, they report outcome
results without using any of the commonly used scales, in
the case of NPH they conclude that high preoperative NFL
levels are associated with favourable surgical outcomes (r
= 0.3, p <= 0.05), and suggest that NFL can be used as a
marker for ongoing axonal damage [68]. However, in
another study from the same group, even though the
increased levels of NFL in the ventricular CSF of patients
with iNPH were verified, the results did not correlate with
improvement [35].
• Sulfatide
Sulfatide is a glycosphingolipid component of myelin and
it has been recently understood by experiments in sul-
fatide-null mice, to be essential for the maintenance of
CNS myelin and axon structure [71]. In an early study, the
role of sulfatide was studied in patients with communicat-
ing hydrocephalus [33]. The preoperative CSF sulfatideCerebrospinal Fluid Research 2006, 3:11 http://www.cerebrospinalfluidresearch.com/content/3/1/11
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levels were found to be higher in the NPH group with cer-
ebrovascular aetiology, when compared with the rest of
the NPH patients. The authors postulated the presence of
irreversible ischemic white matter lesions in the hydro-
cephalic group with cerebrovascular disease. Since the sul-
fatide levels were normal in most of the NPH patients,
they considered that demyelination plays a minor role in
the pathogenesis of NPH. In addition, there was no corre-
lation with surgical outcome. The authors state that the
results cannot be explained by a difference in CSF dynam-
ics and therefore the concentration of sulfatide can differ-
entiate between NPH and subcortical arteriosclerotic
encephalopathy (SAE). The latter condition also known as
Binswanger's disease has a similar clinical presentation to
NPH [72], and therefore this contribution is significant in
establishing the diagnostic role of sulfatide as a biomar-
ker. Tisell et al compared the levels of sulfatide in 37
patients with aqueductal stenosis and iNPH [35]. The lev-
els of sulfatide correlated inversely with improvement in
psychometric performance; this correlation however was
weak.
• Glycoprotein D2
Glycoprotein D2 is a glycoprotein enriched in neuronal
membranes and probably involved in intercellular adhe-
sion. The levels of this protein were examined in the CSF
of 13 hydrocephalic patients and compared with controls
and patients suffering from primary degenerative demen-
tia of Alzheimer's type. The levels were significantly lower
in the case of NPH. No correlation was made with symp-
toms, surgical outcomes or outflow conductance. The sig-
nificance of this study remains unknown in the setting of
NPH [21].
6. Cytokines
Tarkowski et al. investigated the role of the tumour-necro-
sis factor (TNF-α), an inflammatory mediator, and
whether NPH triggers its production [73]. They examined
the levels of TNF-α in the CSF of 35 patients with NPH
and compared them with controls. In the NPH group the
levels were 45-fold higher. The most interesting finding
was that TNF-α returned to control levels following shunt-
ing in the group that improved following surgery. This fac-
tor has a short half-life in CSF, hence accumulation due to
CSF stagnation is unlikely, and the increase may be due to
increased production preoperatively. The authors also
suggest that TNF-α might be a marker for demyelination
and suggest TNF-α toxicity is directed to the white matter
in patients with NPH.
Recently, the CSF levels of two interleukins, IL-4 and IL-
10, have been compared in different neurodegenerative
diseases [74]. Levels of both interleukins were signifi-
cantly higher when compared to controls, but not differ-
ent when compared to patients with dementia and CJD.
The authors suggest that elevated levels of those cytokines
might reflect a response to neurodegeneration, and also
might trigger neuroregeneration. In another study IL-1
levels in the CSF of patients with AD were significantly
higher when compared with NPH [75]. The results of both
studies were not correlated with surgical outcomes. This,
together with the small number of patients, means that it
is not possible to obtain any solid conclusions.
Other biomarkers
We will briefly summarise below studies of biomarkers
that have been investigated less, or only in single studies.
CSF levels of vasopressin did not differ between NPH
patients and controls in two studies of 11 and 18 patients,
respectively. Hammer et al. suggested that there might be
a role of vasopressin affecting the memory, however the
results of the study did not substantiate this claim [20].
The concentrations of corticotropin releasing factor (CRF)
were examined in 14 patients with NPH pre- and postop-
eratively [26]. The levels of CRF increased significantly
post-shunting, nevertheless they remained below normal
levels. The authors explain this difference by a possible
improvement in cerebral blood flow that is known to
occur post shunting. They also noted that the change in
CRF correlated negatively with percentage change in post-
operative verbal fluency and in the trail-making test B, a
test measuring psychomotor speed. No other study has
been identified in the literature and unfortunately we can-
not gain a better insight into the role of CRF with hydro-
cephalus. Levels of cholecystokinin, a 33-amino acid
polypeptide acting as a neurotransmitter or neuromodu-
lator [76], were found to be significantly lower in 16
patients with NPH when compared with controls and also
lower levels were correlated with abnormal intracranial
pressure (ICP) values [77]. Brettschneider et al. studied the
CSF levels of leptomeningeal derived β trace protein,
beta2 microglobulin and cystatin C in groups of patients
suffering from NPH (n = 19), AD (n = 30), vascular (n =
13) and frontotemporal dementia (n = 6). The levels of β-
trace protein were lower in the NPH group than the con-
trols and patients with AD suggesting a meningeal dys-
function in the pathogenesis of NPH. The authors suggest
this protein is a potential biomarker discriminating
between NPH and AD, although no correlation was car-
ried out with surgical outcomes [78].
Discussion
During the recent years, various groups have made efforts
to identify CSF markers for neurodegenerative disorders.
These efforts have so far been concentrated on other neu-
rogenerative disorders such as Alzheimer's dementia [79],
Parkinson's disease [80], Pick's disease, and Lewy Body
dementia [81]. Although improvements of clinical NPH
symptomatology have been described after shunting in
patients with neuropathologically confirmed concomi-Cerebrospinal Fluid Research 2006, 3:11 http://www.cerebrospinalfluidresearch.com/content/3/1/11
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tant Alzheimer's dementia [82], it has been shown that
NPH patients with additional pathology attributed either
to vascular dementia or Alzheimer's disease generally
show worse outcomes after shunting than those with NPH
without concomitant pathology [83]. The pathology of
these conditions is so closely interlinked [53,84,85] that
Silverberg et al. even suggested a low-flow (up to 140 mL/
d) CSF drainage pilot study for patients with Alzheimer's
dementia [86]. Therefore, neurochemical parameters that
could help to separate NPH from other neurological dis-
orders, which mimic NPH symptomatology, would be of
clinical value. Pathological studies have given us an
insight into the changes occurring in chronic hydroceph-
alus. Disruption of the ependymal ventricular lining,
interstitial oedema, neuronal degeneration, white matter
lesions, gliosis, capillary micro-infarctions and demyeli-
nation [45,87-90] are consistent findings. Studies from
experimentally-induced hydrocephalus in rats have sup-
ported these findings and provided additional evidence
[91,92]. Furthermore, we now know that a regenerative
process takes place following gradual necrosis in the white
matter and axonal injury, and as a response there is the
production of new glial cells in the subependymal zone to
compensate for the cell loss [93].
The case for identifying biomarkers in chronic hydroceph-
alus of adult onset has arisen due to similar developments
in other common causes of dementia and the increasing
awareness of both the epidemiology of NPH [3,5] and its
impact on the quality of life of elderly patients [94]. Ide-
ally, useful biomarkers should be confirmed with data
from multiple disciplines, including neuropsychological
testing, blood tests, genetic markers, CSF composition,
and brain imaging. Alterations in the neurochemical com-
position of CSF in hydrocephalus have been widely docu-
mented and reviewed [16]. Newer techniques, which will
be discussed in the next section, will provide us with a
broad spectrum of biological markers ranging from serum
proteins to intracellular mediators that are involved in sig-
nal transduction and transcription [95].
Definition of a biomarker and applications in patients with 
chronic adult hydrocephalus
"The ideal biomarker for Alzheimer's disease (AD) should
detect a fundamental feature of neuropathology and be vali-
dated in neuropathologically-confirmed cases; it should have a
sensitivity of 80% for detecting AD and a specificity of 80% for
distinguishing other dementias; it should be reliable, reproduc-
ible, non-invasive, simple to perform, and inexpensive. Recom-
mended steps to establish a biomarker include confirmation by
at least two independent studies conducted by qualified investi-
gators with the results published in peer-reviewed journals."
This definition given by the Consensus Report of the
Working Group on Molecular and Biochemical Markers of
Alzheimer's disease (Ronald and Nancy Reagan Research
Institute and the NIA Working Group-1998) adequately
highlights the problems that may be faced in attempts to
establish biomarkers for adult-onset communicating
hydrocephalus. The role of a biomarker is to confirm a
diagnosis, serve for epidemiological studies, assess for
prediction, monitoring the progression and response to
treatment and studying brain-behavior relationships. Any
marker will need to be validated against a definite diagno-
sis. Traditionally the diagnosis of NPH was given only
postoperatively on the basis of improvement of the
patient. Recently a collaborative attempt was made to cat-
egorize patients with NPH as 'possible', 'probable' or 'def-
inite' [96]. If this categorization were to be used, then
biomarkers should only be tested in probable cases to
achieve high diagnostic accuracy. The establishment of
control groups is another problem that needs a solution.
Ideally, the spouses of hydrocephalic patients could be
used as controls, as they would be well matched for age,
and environmental and lifestyle factors. However, medi-
cal ethics prohibit us from using invasive procedures
(such as serum or CSF sampling) for research purposes in
healthy individuals. Since one single biomarker might be
inadequate to provide the needed diagnostic accuracy, a
combination of more than one biomarker might give a
solution. An example of this was the study by Lins et al. as
analyzed in an earlier section of this report [63], and as
has already been demonstrated in other neurodegenera-
tive processes [97].
Data synthesis
As we have seen, serum biomarkers appear to be no use at
the present time because relevant studies have been so
few. Serum Glycoprotein D2 was inadequately studied
and therefore may not be used in the differential diagnosis
with patients suffering from primary progressive demen-
tia. Clearly, serum protein concentrations can be influ-
enced by many factors other than brain and CSF
composition, therefore a direct reflection of brain metab-
olism is likely to prove more useful. Studies of biomarkers
in the CSF have been much more numerous although, as
our review has shown, no biomarker has received enough
attention from researchers to emerge with the needed spe-
cificity and sensitivity.
In most of the studies so far there is an observed difference
in the levels of the biomarker preoperatively and postop-
eratively, but there are weak correlations with surgical out-
comes. In other studies there are observed differences
between patients and a control group, but rarely are
results correlated with surgical outcomes. TNF-α emerges
as a potential biomarker. Although the results were not
correlated with surgical outcome, the 45-fold preoperative
increase and return to normal post- shunting, shows the
potential of this marker. However, only one study of 35
patients, reported results for TNf-α, and therefore the dataCerebrospinal Fluid Research 2006, 3:11 http://www.cerebrospinalfluidresearch.com/content/3/1/11
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has yet to be replicated by other research groups. Somato-
statin appears to relate to changes and general impair-
ment of cognitive functions, but bigger studies are
warranted to highlight better this relationship. A signifi-
cant correlation was also found between levels of tau pro-
tein in patients with NPH and the severity of dementia;
again these results need to be replicated. Sulfatide
emerged as a promising biomarker showcasing a sensitiv-
ity of 74% and specificity of 94% in distinguishing
between NPH and subcortical arteriosclerotic encepha-
lopathy. Also, levels of neurofilament triplet protein >640
mg/L have been identified by Tullberg et al. as having a
predictive value of 100% for a positive outcome after
shunt surgery; the latter remain non-sensitive (17%) but
highly specific (100%). Lactate appears a promising dis-
tinguishing factor between different forms of dementia
and further studies correlating lactate levels with surgical
outcomes could reveal its potential as a biomarker.
Technical considerations and existing limitations
There are a few problems of technical nature with using
establishing and validating the use of biomarkers in this
condition. These have been reviewed and acknowledged
by Wood [98]. Firstly, caution should be exercised when
interpreting biochemical results as for many potential
markers there might be no reference values in the CSF of
healthy subjects. There is also a need for age-matched ref-
erence values in the evaluation of CNS pathologies [99].
Wikkelsö et al have noted that in hydrocephalic patients,
low neuropeptide values in the CSF can be caused not
only by reduced release or increased degradation, but also
by an altered distribution volume of the CSF [25]. Indeed
this effect was noted with the MBP studies, levels of which
decreased after flow was restored by shunting. Further-
more increased CSF levels of certain markers might be
explained when one takes in consideration the low CSF
conductance (i.e. increased CSF outflow resistance) in
NPH which compromises the clearance of these metabo-
lites resulting in accumulated levels in the CSF. Another
controversial aspect of studies on concentrations of neu-
ropeptides using lumbar instead of ventricular samples is
whether the effect of the gravity may influence the concen-
tration of the peptides in the samples [100,101].
The dynamics of markers in the CSF differ depending on
whether the proteins derive directly from the nerve cells,
the leptomeninges, or whether they derive from blood
and therefore their concentration and dynamics depend
on the integrity of the blood-brain barrier [102].
Ideally only ventricular samples would be used in the case
of hydrocephalus, even though the spinal absorption
pathways have been shown to be involved in the case of
communicating hydrocephalus [103]. That is because the
ventricular fluid would reflect more accurately the
changes occurring in the periventricular white matter. Ide-
ally the technique of microdialysis, which has been devel-
oped to quantify regional spatial and temporal changes in
brain biochemistry, would be the best tool to monitor
such changes. Indeed, there are publicized attempts in
applying this in patients with NPH [104,105]. However,
ethical issues and technical limitations for detecting puta-
tive markers might be the key issue in pursuing this fur-
ther. It has also been demonstrated that concentrations of
certain markers in the CSF might fluctuate over time, so a
sample at one time point might be of limited use [106].
The sampling during ventricular catheterization seems to
influence the concentrations of certain markers as verified
by two studies [107,108]. This potential pitfall should be
kept in mind in the design of relevant future studies. The
differences in the pathogenesis of the idiopathic and the
secondary form of chronic adult-onset hydrocephalus add
more limitations for data collection from appropriate
populations.
Future directions and possibilities
Proteomics, since its inception in 1995 [109] has showed
great promise in providing a more detailed insight into
the mechanisms of disease in the post-genomic era. The
proteome and peptidome maps can provide us with what
is called "a bird's eye view" of the physiological and path-
ological products and of processes occurring at any one
time. The field of clinical proteomics is especially well
suited for discovery of biological markers in complex bio-
logical fluids, such as plasma, urine, serum and CSF; these
in turn reflect the ongoing biological processes in healthy
subjects, as well as in several neurodegenerative disorders.
The related field of peptidomics is a method for analysing
the vast range of the peptides that have been expressed in
any cell, tissue or fluid at any given time. These two tech-
nologies have already been used successfully to provide us
with an insight into the CSF proteome map [110-114].
Changes in the protein composition of CSF may be indic-
ative of altered CNS protein expression pattern, providing
us with a link to the cause or diagnosis of a condition.
Other areas of neurology have already benefited from this
new area. Mass spectrometry has been used in immunode-
ficiency virus dementia [115], in CSF from patients with
multiple sclerosis [116], and Alzheimer's disease [117], or
for the identification of protein tumour markers in pri-
mary brain tumours [118].
As with every new diagnostic technology, limitations do
exist. At present there is a lack of standardization for the
procedures as the techniques are quite new. A low total-
protein concentration, a high concentration of albumin
and immunoglobins, and a wide range of protein concen-
trations cause several difficulties in the identification of
low-abundance CSF proteins [114]. An attempt to applyCerebrospinal Fluid Research 2006, 3:11 http://www.cerebrospinalfluidresearch.com/content/3/1/11
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proteomics has already been carried out in the H-Tx rat
inherited model of hydrocephalus [119]. A recent attempt
in one single patient identified 82 proteins of which 25
have not appeared in any previously published two-
dimensional electrophoresis (2DE) map of CSF, whereas
eleven of them have not been previously reported to exist
in CSF [111]. Two new peptides related to neuropeptide
FF, a modulator of the opioid system, were detected in the
CSF of one patient with NPH [120]. The significance
remains unknown at present, but these two studies dem-
onstrate the potential to gain a novel insight into areas
that hitherto have not been available.
The need for future collaboration
There is a need for continued and collaborative collection
of research populations of subjects with chronic commu-
nicating hydrocephalus who can contribute to a longitu-
dinal bank of biologic specimens (i.e., imaging data,
biological fluid and genetic samples) for identification
and verification of novel biomarkers. Similar projects in
neurosurgery regarding brain injury (BrainIT) have been
recently attempted and are ongoing. However, since NPH
is mostly a clinical diagnosis with a radiological verifica-
tion, such a biomarker might not be forthcoming even by
the combined efforts of a controlled multicenter trial.
Moreover, collaboration is needed between groups, which
deal with paediatric and adult-type of hydrocephalus.
Although, limitations exist due to the need for data pro-
tection, the long-term gain into the insight in the contin-
uum spectrum of this condition will be immense.
Since follow-up and knowledge of the long-term progno-
sis for the management of this condition is vital, it is nec-
essary to establish common outcome scales which will
allow for multiple study comparisons. As we have seen
outcomes and end points vary widely between groups
dealing with this condition. This effort might also include
establishing a national brain bank project for future col-
laborative research.
Attention should be also given in understanding the epi-
demiology of this condition.
So far, epidemiological data arises mainly from Sweden
due its health system infrastructure. This approach could
also include multiple non-medical disciplines that ulti-
mately influence the outcome of geriatric conditions.
Conclusion
From our literature search, TNF-α, tau, lactate, sulfatide
and neurofilament triple protein in CSF have emerged as
the most promising markers of chronic hydrocephalus.
However, very few studies to date have reported results of
putative biomarkers that have changed our clinical prac-
tice or the way we diagnose chronic adult-type hydroceph-
alus. Most importantly, no single biomarker has fulfilled
all the criteria required. There is currently limited evidence
supporting the role of biomarkers in chronic adult hydro-
cephalus, but it is not sufficient to support a change in
clinical practice. Contributing factors to this, despite 25
years of research, is the fact that the results from different
groups with different philosophy of management have
been inconsistent with criteria regarding the diagnosis or
management of this condition. Furthermore, the small
number of patients in these studies prohibits us from pre-
senting results with adequate statistical power that may
influence or change our current practice. As with other
areas of research these problems may be surpassed by col-
laborative multi-centre projects. Newer bioinformatic
technologies are emerging as promising methods to suc-
cessfully identify biomarkers.
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